Zacks Investment Research announced INC Research Holdings Inc (NASDAQ:INCR), upping its target price to $51.00 earlier today
- Updated: September 17, 2016
Indicating a possible upside of 0.11%, Zacks Investment Research upped the price target of INC Research Holdings Inc (NASDAQ:INCR) to $51.
Previously on Wednesday August 17 2016, Jefferies & Co released a statement for INC Research Holdings Inc(NASDAQ:INCR) lowered the target price from $56.00 to $55.00 that indicated a possible upside of 0.21%.
Showing a price of $45.92, INC Research Holdings Inc (NASDAQ:INCR) traded 0.14% lower on the day. The last close is up 0.59% relative to the 200-day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. INC Research Holdings Inc has registered a 50-day average of $44.36 and two hundred day moving average of $43.13. Trading volume was was down over the average, with 687,069 shares of INCR changing hands under the typical 872,027 shares.
See Chart Below:
INC Research Holdings Inc has a 52 week low of $34.19 and a one-year high of $57.11 with a price-earnings ratio of 21 and has a total market value of $0.0.
A total of 7 brokers have reported on INC Research Holdings Inc. Three firms rate the stock a strong buy, four firms rate the stock a buy, three analyts rate the stock a hold, 0 rate the company to underperform, and finally 0 brokeragesrate the stock as sell with a one year target stock price of $52.43
General Company Details For INC Research Holdings Inc (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, and first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.